| Gene symbol | MAGEA3 | Synonyms | CT1.3, HIP8, HYPD, MAGE3, MAGEA6 | Type of gene | protein-coding | |
| Chromosome | X | Map location | Xq28 | dbXrefs | Entrez:4102 MIM:300174 HGNC:HGNC:6801 Ensembl:ENSG00000221867 AllianceGenome:HGNC:6801 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | MAGE family member A3 | |||||
| Gene symbol | MAGEA6 | Synonyms | CT1.6, MAGE-3b, MAGE3B, MAGE6 | Type of gene | protein-coding | |
| Chromosome | X | Map location | Xq28 | dbXrefs | Entrez:4105 MIM:300176 HGNC:HGNC:6804 Ensembl:ENSG00000197172 AllianceGenome:HGNC:6804 | |
| Description | MAGE family member A6 | |||||
| GTO ID | GTC1724 |
| Trial ID | NCT03139370 |
| Disease | Solid Tumor |
| Altered gene | MAGE-A3|MAGE-A6 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KITE-718 |
| HLA | HLA-DPB1*04:01 |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers |
| Year | 2017 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KITE-718-301|2020-005456-37 |
| Cohort 1 | |||||||||
|
|||||||||